AKT2: RAC-beta serine/threonine-protein kinase
Serine/threonine kinase closely related to AKT1 and AKT3.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on AKT2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| BAY-1125976 | Phase 1 | Bayer | Small molecule | InhibitorSerine/threonine-protein kinase AKT2 inhibitor | 0 |
- Hypoinsulinemic hypoglycemia and body hemihypertrophy0.79
- Type 2 diabetes mellitus0.72
- Breast cancer0.57
- Diabetes mellitus0.52
- Cancer0.43
- Neoplasm0.42
- Lung carcinoma0.39
- Triple-negative breast carcinoma0.39
- Prostate cancer0.39
- Neurodegenerative disease0.39
- AKT2-related familial partial lipodystrophy0.39
- Prostate carcinoma0.38
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2431, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P31751, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets